한빛사논문
- 조회459
Hye Jin Kim a,1, Hongrae Kim a,b,1, Dongsung Park a,b, Dae Sung Yoon b, Jin San Lee c, Kyo Seon Hwang a
aDepartment of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea
bSchool of Biomedical Engineering, Korea University, Seoul, 02841, Republic of Korea
cDepartment of Neurology, Kyung Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea
1These authors contributed equally to this study.
Corresponding authors: Jin San Lee, Kyo Seon Hwang
Abstract
Using biosensor to screen for Alzheimer's disease (AD) facilitates early detection of AD with high sensitivity and accuracy. This approach overcomes the limitations of conventional AD diagnostic methods, such as neuropsychological assessment and neuroimaging analysis. Here, we propose a simultaneous analysis of signal combinations generated by four crucial AD biomarkers (Amyloid beta 1-40 (Aβ40), Aβ42, total tau 441 (tTau441), and phosphorylated tau 181 (pTau181)) by inducing a dielectrophoretic (DEP) force on fabricated interdigitated microelectrode (IME) sensor. By applying an optimal DEP force, our biosensor selectively concentrates and filters the plasma-based AD biomarkers, exhibiting high sensitivity (limit of detection <100 fM) and selectivity in the plasma-based AD biomarkers detection (p < 0.0001). Consequently, it is demonstrated that a complex combined signal comprising four AD-specific biomarker signals (Aβ40- Aβ42+ tTau441- pTau181) can differentiate between patients with AD and healthy subjects with high accuracy (78.85%) and precision (80.95%) (p < 0.0001).
논문정보
- Research article
- 2023년 06월 (BRIC 등록일 2023-06-09)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
